The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
Background/Objectives: A significant breakthrough in non-small-cell lung cancer (NSCLC) treatment has occurred with the introduction of targeted therapies and immunotherapy. However, not all patients treated with these therapies would respond to treatment, and patients who respond to treatment would...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/47/1/45 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588787488653312 |
|---|---|
| author | Vesna Ćeriman Krstić Dragana Jovanović Natalija Samardžić Milija Gajić Jelena Kotur Stevuljević Aleksandra Klisic Ivan Soldatović Damir Radončić Marina Roksandić Milenković Biljana Šeha Nikola Čolić Katarina Lukić Milan Savić |
| author_facet | Vesna Ćeriman Krstić Dragana Jovanović Natalija Samardžić Milija Gajić Jelena Kotur Stevuljević Aleksandra Klisic Ivan Soldatović Damir Radončić Marina Roksandić Milenković Biljana Šeha Nikola Čolić Katarina Lukić Milan Savić |
| author_sort | Vesna Ćeriman Krstić |
| collection | DOAJ |
| description | Background/Objectives: A significant breakthrough in non-small-cell lung cancer (NSCLC) treatment has occurred with the introduction of targeted therapies and immunotherapy. However, not all patients treated with these therapies would respond to treatment, and patients who respond to treatment would acquire resistance at some time point. This is why we need new biomarkers that can predict response to therapy. The aim of this study was to investigate whether soluble programmed cell death-ligand 1 (sPD-L1) could be a predictive biomarker in patients with epidermal growth factor receptor (EGFR)-positive NSCLC. Materials and Methods: Blood samples from 35 patients with EGFR-mutated (EGFRmut) adenocarcinoma who achieved disease control with EGFR tyrosine kinase inhibitor (EGFR TKI) therapy were collected for sPD-L1 analysis. We analyzed sPD-L1 concentrations in 30 healthy middle-aged subjects, as a control population, to determine the reference range. Adenocarcinoma patients were divided into two groups, i.e., a group with low sPD-L1 (≤182.5 ng/L) and a group with high sPD-L1 (>182.5 ng/L). Results: We found that progression-free survival (PFS) was 18 months, 95% CI (11.1–24.9), for patients with low sPD-L1 and 25 months, 95% CI (8.3–41.7), for patients with high sPD-L1. There was no statistically significant difference in PFS between the groups (<i>p</i> = 0.100). Overall survival (OS) was 34.4 months, 95% CI (26.6–42.2), for patients with low sPD-L1 and 84.1 months, 95% CI (50.6–117.6), for patients with high sPD-L1; there was also no statistically significant difference between the groups (<i>p</i> = 0.114). Conclusion: In our study, we found that patients with high sPD-L1 had numerically better PFS and OS, but this has no statistical significance. Further studies with a larger number of patients are needed to evaluate the role of sPD-L1 as a predictive biomarker in patients with EGFRmut NSCLC. |
| format | Article |
| id | doaj-art-a1de011d752147a088b7f88667699dbb |
| institution | Kabale University |
| issn | 1467-3037 1467-3045 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Issues in Molecular Biology |
| spelling | doaj-art-a1de011d752147a088b7f88667699dbb2025-01-24T13:27:31ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452025-01-014714510.3390/cimb47010045The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung CancerVesna Ćeriman Krstić0Dragana Jovanović1Natalija Samardžić2Milija Gajić3Jelena Kotur Stevuljević4Aleksandra Klisic5Ivan Soldatović6Damir Radončić7Marina Roksandić Milenković8Biljana Šeha9Nikola Čolić10Katarina Lukić11Milan Savić12Faculty of Medicine, University of Belgrade, 11000 Belgrade, SerbiaInternal Medicine Clinic “Akta Medica”, 11000 Belgrade, SerbiaClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, SerbiaClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, SerbiaDepartment for Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, SerbiaFaculty of Medicine, University of Montenegro, 81000 Podgorica, MontenegroInstitute of Medical Statistics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, SerbiaClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, SerbiaMunicipal Institute for Lung Diseases and TB, 11000 Belgrade, SerbiaClinic for Neurosurgery, University Clinical Center of Serbia, 11000 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, 11000 Belgrade, SerbiaCenter for Radiology, University Clinical Center of Serbia, 11000 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, 11000 Belgrade, SerbiaBackground/Objectives: A significant breakthrough in non-small-cell lung cancer (NSCLC) treatment has occurred with the introduction of targeted therapies and immunotherapy. However, not all patients treated with these therapies would respond to treatment, and patients who respond to treatment would acquire resistance at some time point. This is why we need new biomarkers that can predict response to therapy. The aim of this study was to investigate whether soluble programmed cell death-ligand 1 (sPD-L1) could be a predictive biomarker in patients with epidermal growth factor receptor (EGFR)-positive NSCLC. Materials and Methods: Blood samples from 35 patients with EGFR-mutated (EGFRmut) adenocarcinoma who achieved disease control with EGFR tyrosine kinase inhibitor (EGFR TKI) therapy were collected for sPD-L1 analysis. We analyzed sPD-L1 concentrations in 30 healthy middle-aged subjects, as a control population, to determine the reference range. Adenocarcinoma patients were divided into two groups, i.e., a group with low sPD-L1 (≤182.5 ng/L) and a group with high sPD-L1 (>182.5 ng/L). Results: We found that progression-free survival (PFS) was 18 months, 95% CI (11.1–24.9), for patients with low sPD-L1 and 25 months, 95% CI (8.3–41.7), for patients with high sPD-L1. There was no statistically significant difference in PFS between the groups (<i>p</i> = 0.100). Overall survival (OS) was 34.4 months, 95% CI (26.6–42.2), for patients with low sPD-L1 and 84.1 months, 95% CI (50.6–117.6), for patients with high sPD-L1; there was also no statistically significant difference between the groups (<i>p</i> = 0.114). Conclusion: In our study, we found that patients with high sPD-L1 had numerically better PFS and OS, but this has no statistical significance. Further studies with a larger number of patients are needed to evaluate the role of sPD-L1 as a predictive biomarker in patients with EGFRmut NSCLC.https://www.mdpi.com/1467-3045/47/1/45NSCLCEGFRsPD-L1PD-L1immunotherapymolecular therapy |
| spellingShingle | Vesna Ćeriman Krstić Dragana Jovanović Natalija Samardžić Milija Gajić Jelena Kotur Stevuljević Aleksandra Klisic Ivan Soldatović Damir Radončić Marina Roksandić Milenković Biljana Šeha Nikola Čolić Katarina Lukić Milan Savić The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer Current Issues in Molecular Biology NSCLC EGFR sPD-L1 PD-L1 immunotherapy molecular therapy |
| title | The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer |
| title_full | The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer |
| title_fullStr | The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer |
| title_full_unstemmed | The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer |
| title_short | The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer |
| title_sort | potential role of spd l1 as a predictive biomarker in egfr positive non small cell lung cancer |
| topic | NSCLC EGFR sPD-L1 PD-L1 immunotherapy molecular therapy |
| url | https://www.mdpi.com/1467-3045/47/1/45 |
| work_keys_str_mv | AT vesnacerimankrstic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT draganajovanovic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT natalijasamardzic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT milijagajic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT jelenakoturstevuljevic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT aleksandraklisic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT ivansoldatovic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT damirradoncic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT marinaroksandicmilenkovic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT biljanaseha thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT nikolacolic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT katarinalukic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT milansavic thepotentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT vesnacerimankrstic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT draganajovanovic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT natalijasamardzic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT milijagajic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT jelenakoturstevuljevic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT aleksandraklisic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT ivansoldatovic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT damirradoncic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT marinaroksandicmilenkovic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT biljanaseha potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT nikolacolic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT katarinalukic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer AT milansavic potentialroleofspdl1asapredictivebiomarkerinegfrpositivenonsmallcelllungcancer |